CLXCLX
US • —
$95.44
P/E
15.50
PEG
1.46
FCF Yield
—
Rev Growth YoY
-3.7% YoY
Gross Margin
43.9%
Health Score
4/10
D/E Ratio
7.86
Confidence
LOW
Business Snapshot
The Clorox Company manufactures and markets consumer and professional cleaning products, including its namesake bleach and cleaning solutions. It operates in the household and personal care sector, holding a position as an established brand with significant market presence in its core categories. The company's financial scale is not fully disclosed, as TTM revenue data is unavailable. A defining characteristic is its substantial brand equity in the cleaning and disinfecting space, which provides some competitive resilience. However, the absence of market cap and revenue data limits a full assessment of its size and financial reach.
Financial Health
Gross margin stands at 43.9%, while net margin is 11.2%, but no prior year data is available to assess the trend. The balance sheet appears stretched, with a debt-to-equity ratio of 7.86x indicating high leverage, and a current ratio of 0.84x suggesting potential short-term liquidity pressure...
Risk Assessment
- DEBT / LIQUIDITY — Debt/equity of 7.86x reflects a highly leveraged balance sheet, while the current ratio of 0.84x indicates potential near-term liquidity risk.
- EARNINGS QUALITY — 3 of the last 4 quarters beat estimates, which is not a red flag; however, the revenue decline of 3.7% YoY undercuts the quality of reported earnings growth.
- REVENUE DECELERATION — Revenue declined 3.7% year-over-year, a reversal that contrasts with typical growth expectations and signals operational headwinds.
- VALUATION DIVERGENCE — Price/Book of 46.1x is extremely elevated, suggesting the market assigns minimal value to tangible assets relative to the stock price.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed....
Gross margin stands at 43.9%, while net margin is 11.2%, but no prior year data is available to assess the trend. The balance sheet appears stretched, with a debt-to-equity ratio of 7.86x indicating high leverage, and a current ratio of 0.84x suggesting potential short-term liquidity pressure. Free cash flow data is not provided, making it impossible to evaluate the company's cash generation or its ability to self-fund operations. Overall, the financial health is concerning due to elevated debt and uncertain liquidity, which could limit financial flexibility and dividend security.
- DEBT / LIQUIDITY — Debt/equity of 7.86x reflects a highly leveraged balance sheet, while the current ratio of 0.84x indicates potential near-term liquidity risk. - EARNINGS QUALITY — 3 of the last 4 quarters beat estimates, which is not a red flag; however, the revenue decline of 3.7% YoY undercuts the quality of reported earnings growth. - REVENUE DECELERATION — Revenue declined 3.7% year-over-year, a reversal that contrasts with typical growth expectations and signals operational headwinds. - VALUATION DIVERGENCE — Price/Book of 46.1x is extremely elevated, suggesting the market assigns minimal value to tangible assets relative to the stock price. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives